A systematic review of the stability of finished pharmaceutical products and drug substances beyond their labeled expiry dates

J Pharm Biomed Anal. 2019 Mar 20;166:222-235. doi: 10.1016/j.jpba.2019.01.016. Epub 2019 Jan 11.

Abstract

In recent years, there has been a very active debate about the stability of drug products especially after exceeding the expiry dates. The regulatory authorities require comprehensive stability data for market approval. The shelf-life obtained determines the expiry date, which is typically between 1 and 5 years and commonly set in a conservative manner. Conducting stability studies is a resource- and time-consuming matter for the pharmaceutical manufacturer. Short shelf-lives of drug products are also a challenge for managers of hospitals, nursing homes, and strategic national stockpile agencies which have to dispose of large quantities of outdated medicines every year. This conflict raises the question whether shelf-lives are often longer than the labeled one. In the past years, the FDA has launched several programs for shelf-life extension in order to defer replacement costs and to prevent drug shortages due to supply disruption. The aim of this review was to bring together the available literature of expired drug products as well as historical pharmaceutical relicts with an age of more than 80 years and to discuss the actual shelf-life with regard to the respective dosage form and the affiliation of the drug class. It seems to be reasonable for a large portion of drugs to extend the expiry dates far beyond five years.

Keywords: Content; Degradation; Expiry date; Long-term stability; Old drug product; Shelf-life.

Publication types

  • Systematic Review

MeSH terms

  • Dosage Forms
  • Drug Labeling / standards*
  • Drug Stability*
  • Pharmaceutical Preparations / classification
  • Pharmaceutical Preparations / standards*
  • Quality Control
  • Time Factors

Substances

  • Dosage Forms
  • Pharmaceutical Preparations